This Article Full Text (PDF) Other Versions of this Article: IAI.00374-08v1 76/8/3664    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Huntley, J. F. Articles by Norgard, M. V. PubMed PubMed Citation Articles by Huntley, J. F. Articles by Norgard, M. V.

 Previous Article  |  Next Article 

Infect. Immun. doi:10.1128/IAI.00374-08
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Native Outer Membrane Proteins Protect Mice Against Pulmonary Challenge with Virulent Type A Francisella tularensis

Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, 75390; Department of Microbiology, Roy J. and Lucille A. Carver School of Medicine, University of Iowa, Iowa City, Iowa, 52242

^* To whom correspondence should be addressed. Email: michael.norgard{at}utsouthwestern.edu.

	Abstract

Francisella tularensis is a Gram-negative intracellular bacterium and the causative agent of the zoonotic disease tularemia. F. tularensis is a Category A select agent and thus a potential agent of bioterrorism. Whereas a live, attenuated vaccine strain of F. tularensis (LVS) is the basis of an investigational vaccine, it is not licensed for human use because of efficacy and safety concerns. In the present study, we immunized mice with isolated native outer membrane proteins (OMPs), ethanol-inactivated LVS (iLVS), or purified LVS lipopolysaccharide (LPS) and assessed the ability of each vaccine preparation to protect mice against pulmonary challenge with the virulent Type A F. tularensis strain SchuS4. Antibody isotyping indicated that both Th1 and Th2 antibody responses were generated in mice after immunization with OMPs or iLVS, whereas LPS immunization resulted in IgA production only. In survival studies, OMP immunization afforded the greatest level of protection (50% survival at 20 days post-infection with SchuS4), with associated 3-log reductions in spleen and liver bacterial burdens (compared to non-vaccinated mice). Cytokine quantitation from the sera of SchuS4-challenged mice indicated that OMP and iLVS immunizations induced high amounts of TNF- and IL-2 production, whereas only OMP immunization induced high levels of IL-10. By comparison, high levels of pro-inflammatory cytokines, including RANTES, G-CSF, IL-6, IL-1, IL-12p40, and KC in non-vaccinated mice indicated that these cytokines may facilitate disease progression. Taken together, this study demonstrates the potential utility of an OMP subunit (acellular) vaccine in protecting mammals against Type A F. tularensis.